McCann FitzGerald advises Horizon Pharma plc in relation to its US$475 million share offering

We acted as Irish counsel to Horizon Pharma plc in relation to its underwritten public offering of 17,652,500 of its ordinary shares at a price to the public of $28.25 per share. The aggregate net proceeds to Horizon from this offering were approximately $475.2 million, after deducting underwriting discounts and other offering expenses payable by Horizon.